{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T02:03:08Z","timestamp":1779933788233,"version":"3.53.1"},"reference-count":40,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T00:00:00Z","timestamp":1726272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Instituto Carlos III","award":["PI19\/0518"],"award-info":[{"award-number":["PI19\/0518"]}]},{"name":"Instituto Carlos III","award":["PI22\/1088"],"award-info":[{"award-number":["PI22\/1088"]}]},{"name":"CRIS Foundation","award":["PI19\/0518"],"award-info":[{"award-number":["PI19\/0518"]}]},{"name":"CRIS Foundation","award":["PI22\/1088"],"award-info":[{"award-number":["PI22\/1088"]}]},{"name":"European Regional Development Fund (ERDF)","award":["PI19\/0518"],"award-info":[{"award-number":["PI19\/0518"]}]},{"name":"European Regional Development Fund (ERDF)","award":["PI22\/1088"],"award-info":[{"award-number":["PI22\/1088"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Despite advances in diagnosis of erythrocytosis and thrombocytosis due to driver mutation testing, many cases remain classified as \u201cidiopathic\u201d. This can be explained by the absence of an evident secondary cause, inconclusive bone marrow biopsy or neglection of family history. Analysis of a broad panel of genes through next-generation sequencing (NGS) could improve diagnostic work-up identifying underlying genetic causes. We reviewed the results of NGS performed in our laboratory and its diagnostic impact on 117 patients with unexplained erythrocytosis and 58 with unexplained thrombocytosis; six patients (5.1%) were diagnosed with polycythaemia vera (PV) and 8 (6.8%) with familial erythrocytosis after NGS testing. Low EPO and a family history seemed to predict a positive result, respectively. However, a greater percentage of patients were ultimately diagnosed with secondary erythrocytosis (36%), remained as idiopathic (28.2%) or were self-limited (15%). The yield of NGS was shown to be slightly higher in patients with thrombocytosis, as 15 (25.9%) were diagnosed with essential thrombocythemia (ET) or familial thrombocytosis after variant detection; previous research has shown similar results, but most of them carried out NGS retrospectively, while the present study exhibits the performance of this test in a real-world setting. Overall, the low rate of variant detection and its poor impact on diagnostic work-up highlights the need for a thorough screening prior to NGS, in order to improve its yield.<\/jats:p>","DOI":"10.3390\/cancers16183149","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T10:56:57Z","timestamp":1726484217000},"page":"3149","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Impact of Deep Targeted Sequencing on Erythrocytosis and Thrombocytosis Diagnosis: A Reference Centre Experience"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7637-7283","authenticated-orcid":false,"given":"Alberto","family":"Blanco-S\u00e1nchez","sequence":"first","affiliation":[{"name":"Centro Nacional de Investigaciones Oncol\u00f3gicas, Complutense University, 28029 Madrid, Spain"},{"name":"Hematology Department, Hospital Universitario 12 de Octubre, I + 12, 28041 Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Oncolog\u00eda, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2093-7119","authenticated-orcid":false,"given":"Rodrigo","family":"Gil-Manso","sequence":"additional","affiliation":[{"name":"Centro Nacional de Investigaciones Oncol\u00f3gicas, Complutense University, 28029 Madrid, Spain"},{"name":"Hematology Department, Hospital Universitario 12 de Octubre, I + 12, 28041 Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Oncolog\u00eda, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"de Nicol\u00e1s","sequence":"additional","affiliation":[{"name":"Centro Nacional de Investigaciones Oncol\u00f3gicas, Complutense University, 28029 Madrid, Spain"},{"name":"Hematology Department, Hospital Universitario 12 de Octubre, I + 12, 28041 Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Oncolog\u00eda, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nieves","family":"L\u00f3pez-Mu\u00f1oz","sequence":"additional","affiliation":[{"name":"Centro Nacional de Investigaciones Oncol\u00f3gicas, Complutense University, 28029 Madrid, Spain"},{"name":"Hematology Department, Hospital Universitario 12 de Octubre, I + 12, 28041 Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Oncolog\u00eda, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5761-886X","authenticated-orcid":false,"given":"Rafael","family":"Colmenares","sequence":"additional","affiliation":[{"name":"Centro Nacional de Investigaciones Oncol\u00f3gicas, Complutense University, 28029 Madrid, Spain"},{"name":"Hematology Department, Hospital Universitario 12 de Octubre, I + 12, 28041 Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Oncolog\u00eda, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reyes","family":"Mas","sequence":"additional","affiliation":[{"name":"Centro Nacional de Investigaciones Oncol\u00f3gicas, Complutense University, 28029 Madrid, Spain"},{"name":"Hematology Department, Hospital Universitario 12 de Octubre, I + 12, 28041 Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Oncolog\u00eda, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6383-0381","authenticated-orcid":false,"given":"Ricardo","family":"S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Centro Nacional de Investigaciones Oncol\u00f3gicas, Complutense University, 28029 Madrid, Spain"},{"name":"Hematology Department, Hospital Universitario 12 de Octubre, I + 12, 28041 Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Oncolog\u00eda, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Rapado","sequence":"additional","affiliation":[{"name":"Centro Nacional de Investigaciones Oncol\u00f3gicas, Complutense University, 28029 Madrid, Spain"},{"name":"Hematology Department, Hospital Universitario 12 de Octubre, I + 12, 28041 Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Oncolog\u00eda, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7908-0063","authenticated-orcid":false,"given":"Joaqu\u00edn","family":"Mart\u00ednez-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Centro Nacional de Investigaciones Oncol\u00f3gicas, Complutense University, 28029 Madrid, Spain"},{"name":"Hematology Department, Hospital Universitario 12 de Octubre, I + 12, 28041 Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Oncolog\u00eda, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2699-8353","authenticated-orcid":false,"given":"Rosa Ayala","family":"D\u00edaz","sequence":"additional","affiliation":[{"name":"Centro Nacional de Investigaciones Oncol\u00f3gicas, Complutense University, 28029 Madrid, Spain"},{"name":"Hematology Department, Hospital Universitario 12 de Octubre, I + 12, 28041 Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Oncolog\u00eda, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9570-5542","authenticated-orcid":false,"given":"Gonzalo","family":"Carre\u00f1o-Tarragona","sequence":"additional","affiliation":[{"name":"Centro Nacional de Investigaciones Oncol\u00f3gicas, Complutense University, 28029 Madrid, Spain"},{"name":"Hematology Department, Hospital Universitario 12 de Octubre, I + 12, 28041 Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Oncolog\u00eda, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/bjh.15648","article-title":"A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline","volume":"184","author":"McMullin","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Pizzi, M., Croci, G.A., Ruggeri, M., Tabano, S., Dei Tos, A.P., Sabattini, E., and Gianelli, U. (2021). The classification of myeloproliferative neoplasms: Rationale, historical background and future perspectives with focus on unclassifiable cases. Cancers, 13.","DOI":"10.3390\/cancers13225666"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/ajh.26008","article-title":"Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management","volume":"95","author":"Tefferi","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.pathol.2023.09.012","article-title":"Variability of bone marrow biopsy reporting affects accuracy of diagnosis of myeloproliferative neoplasms: Data from the ALLG MPN01 registry","volume":"56","author":"Ng","year":"2024","journal-title":"Pathology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1182\/blood-2008-01-135897","article-title":"Characteristics and clinical correlates of MPL 515W>L\/K mutation in essential thrombocythemia","volume":"112","author":"Vannucchi","year":"2008","journal-title":"Blood"},{"key":"ref_8","unstructured":"(2024, September 05). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Myeloproliferative Neoplasms Version 2.2024\u20138 August 2024. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mpn.pdf."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1182\/blood-2016-10-695957","article-title":"Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms","volume":"129","author":"Rumi","year":"2017","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1038\/s41375-021-01290-6","article-title":"JAK2 unmutated erythrocytosis: Current diagnostic approach and therapeutic views","volume":"35","author":"Gangat","year":"2021","journal-title":"Leukemia"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Cattaneo, D., Croci, G.A., Bucelli, C., Tabano, S., Cannone, M.G., Gaudioso, G., Barbanti, M.C., Barbullushi, K., Bianchi, P., and Fermo, E. (2021). Triple-Negative Essential Thrombocythemia: Clinical-Pathological and Molecular Features. A Single-Center Cohort Study. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.637116"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1182\/asheducation-2009.1.629","article-title":"Idiopathic erythrocytosis: A disappearing entity","volume":"2009","author":"Mcmullin","year":"2009","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/ijlh.12686","article-title":"Frequency of polycythemia in individuals with normal complete blood cell counts according to the new 2016 WHO classification of myeloid neoplasms","volume":"39","author":"Sandes","year":"2017","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1182\/blood-2014-06-583161","article-title":"Presence of calreticulin mutations in JAK2-negative polycythemia vera","volume":"124","author":"Park","year":"2014","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1182\/blood-2010-02-270108","article-title":"Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms","volume":"116","author":"Oh","year":"2010","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/bjh.17741","article-title":"Hereditary thrombocytosis: The genetic landscape","volume":"194","author":"Han","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1038\/s41375-021-01239-9","article-title":"A typical acute lymphoblastic leukemia JAK2 variant, R683G, causes an aggressive form of familial thrombocytosis when germline","volume":"35","author":"Varghese","year":"2021","journal-title":"Leukemia"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Bellann\u00e9-Chantelot, C., Mosca, M., Marty, C., Favier, R., Vainchenker, W., and Plo, I. (2017). Identification of MPL R102P Mutation in Hereditary Thrombocytosis. Front. Endocrinol., 8.","DOI":"10.3389\/fendo.2017.00235"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/bjh.16249","article-title":"A decade with whole exome sequencing in haematology","volume":"188","author":"Hansen","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.humimm.2021.02.006","article-title":"Applications of next-generation sequencing in hematologic malignancies","volume":"82","author":"Ramkissoon","year":"2021","journal-title":"Hum. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.3324\/haematol.2016.144063","article-title":"Gene panel sequencing improves the diagnostic work-up of patients with idiopathic erythrocytosis and identifies new mutations","volume":"101","author":"Camps","year":"2016","journal-title":"Haematologica"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3056216","DOI":"10.1155\/2024\/3056216","article-title":"An Approach to the Investigation of Thrombocytosis: Differentiating between Essential Thrombocythemia and Secondary Thrombocytosis","volume":"2024","author":"Almanaseer","year":"2024","journal-title":"Adv. Hematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"7209","DOI":"10.3390\/curroncol29100568","article-title":"Mutational Landscape of Patients Referred for Elevated Hemoglobin Level","volume":"29","author":"Bhai","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e2024021","DOI":"10.4084\/MJHID.2024.021","article-title":"Coexistence of multiple gene variants in some patients with erythrocytoses","volume":"16","author":"Benetti","year":"2024","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Jalowiec, K.A., Vrotniakaite-Bajerciene, K., Jalowiec, J., Frey, N., Capraru, A., Wojtovicova, T., Joncourt, R., Angelillo-Scherrer, A., Tichelli, A., and Porret, N.A. (2022). JAK2 Unmutated Polycythaemia\u2014Real-World Data of 10 Years from a Tertiary Reference Hospital. J. Clin. Med., 11.","DOI":"10.3390\/jcm11123393"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40291-024-00703-3","article-title":"Diagnostic Approaches to Investigate JAK2-Unmutated Erythrocytosis Based on a Single Tertiary Center Experience","volume":"28","author":"Lee","year":"2024","journal-title":"Mol. Diagn. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood-2015-07-661835","article-title":"Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms","volume":"127","author":"Feenstra","year":"2016","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer","volume":"19","author":"Li","year":"2017","journal-title":"J. Mol. Diagn."},{"key":"ref_29","first-page":"E150","article-title":"Serum erythropoietin levels in 696 patients investigated for erythrocytosis with JAK2 mutation analysis","volume":"97","author":"Cheong","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_30","first-page":"3143","article-title":"How I Communicate with Patients and Families about Germline Genetic Information","volume":"141","author":"Hamilton","year":"2023","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2017-02-735290","article-title":"Genetic predisposition to hematologic malignancies: Management and surveillance","volume":"130","author":"Godley","year":"2017","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2352-3026(19)30211-X","article-title":"Assessing clonal haematopoiesis: Clinical burdens and benefits of diagnosing myelodysplastic syndrome precursor states","volume":"7","author":"Gondek","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ccr3.2720","article-title":"Diagnosis of exon 12-positive polycythemia vera rescued by NGS","volume":"8","author":"Geay","year":"2020","journal-title":"Clin. Case Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"6353","DOI":"10.1182\/bloodadvances.2020003323","article-title":"Erythrocytosis in the general population: Clinical characteristics and association with clonal hematopoiesis","volume":"4","author":"Wouters","year":"2020","journal-title":"Blood Adv."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.3324\/haematol.2022.280917","article-title":"Histological and genetic characterization and follow-up of 130 patients with chronic triple-negative thrombocytosis","volume":"107","author":"Lemoine","year":"2022","journal-title":"Haematologica"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"E264","DOI":"10.1002\/ajh.25580","article-title":"Diagnostic and prognostic contribution of targeted NGS in patients with triple-negative myeloproliferative neoplasms","volume":"94","author":"Acha","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1136\/jclinpath-2020-206570","article-title":"Mutational profiling in suspected triple-negative essential thrombocythaemia using targeted next-generation sequencing in a real-world cohort","volume":"74","author":"Michail","year":"2021","journal-title":"J. Clin. Pathol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/leu.2015.360","article-title":"Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: Comparison between the BCSH and the WHO criteria","volume":"30","author":"Gisslinger","year":"2016","journal-title":"Leukemia"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2141.2010.08122.x","article-title":"Guideline for investigation and management of adults and children presenting with a thrombocytosis","volume":"149","author":"Harrison","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and Personalized Prognosis in Myeloproliferative Neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N. Eng. J. Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/18\/3149\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:56:06Z","timestamp":1760111766000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/18\/3149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,14]]},"references-count":40,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["cancers16183149"],"URL":"https:\/\/doi.org\/10.3390\/cancers16183149","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,14]]}}}